WHO Approves Serum Institute’s Novavax Vaccine for Emergency Use

The World Health Organization (WHO) has approved the COVID-19 vaccine Covovax for emergency use, which is the Serum Institute of India‘s (SII) version of the Novavax vaccine.

The World Health Organization (WHO) has approved the COVID-19 vaccine Covovax, which is the Serum Institute of India‘s (SII) version of the Novavax vaccine, for emergency use. “The vaccine, manufactured by Serum Institute under license from US-based Novavax, will now be distributed as Covavax under the Global Vaccine Sharing System,” a statement issued by the WHO said.

Mariangela Simao, Head of Access to Vaccines, World Health Organization, said, “At a time when new variants are emerging, vaccines are the most effective way to protect people from serious illness and death caused by SARS-COV-2.” The aim of this step is to increase the reach of the vaccine, especially in low-income countries. He said that 41 of the low-income countries have still not been able to provide vaccine to 10 percent of their population, while 98 countries have not even reached 40 percent of the vaccine.

Reviewer overview

WHO Approves Serum Institute's Novavax Vaccine for Emergency Use - /10

Summary

The World Health Organization (WHO) has approved the COVID-19 vaccine Covovax for emergency use, which is the Serum Institute of India's (SII) version of the Novavax vaccine.

0 Bad!